A Multicenter, Randomized, Double-blinded, Placebo-controlled Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Interleukin-7 (Primary) ; Interleukin-7 (Primary)
- Indications Lymphopenia; Sepsis
- Focus Adverse reactions; Therapeutic Use
- Acronyms IRIS-7A
- 17 Oct 2017 Planned End Date changed from 1 Jul 2017 to 8 Feb 2018.
- 17 Oct 2017 Status changed from recruiting to discontinued.
- 10 Jun 2017 Biomarkers information updated